Likewise, a large database-study assessing characteristics and outcomes of NSCLC patients carrying multiple molecular alterations showed that cases with EGFR/KRAS and EGFR/PIK3CA co-mutations were associated with shorter PFS during TKI-treatment than patients with only EGFR-mutations [44]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.